PEARL RIVER, N.Y., November 06, 2023 Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Up to five approvals expected in 2024Additional filings expected in Chile in late 2023 and in Mexico and Brazil in 2024PEARL RIVER, N.Y. (BUSINESS WIRE) Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for
Acorda Therapeutics (ACOR) Announces Esteve Launches INBRIJA in Germany streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
16.06.2022 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic . Seite 1